Hubexel Obtains Manufacturing License for New AEON-C Medical Device... "Expecting Increased Performance"

[Asia Economy Reporter Yoo Hyun-seok] Hubexel, a medical device specialist company, announced on the 7th that it has obtained medical device manufacturing approval from the Ministry of Food and Drug Safety for its new intervertebral fusion implant (AEON-C). This domestic approval was completed following the announcement on the 2nd of acquiring two patents for ‘intervertebral fusion fixation device’ and ‘detachable intervertebral fusion fixation device’.

With this acquisition, Hubexel now holds a total of 16 patents (including one U.S. patent). The domestic approval for AEON-C (a patented product) has been finalized. This enables domestic sales as well as exports to South Africa and the UAE.

Meanwhile, in July, Hubexel acquired BioOrigin, a company possessing core biomaterial technology, and incorporated it as a subsidiary. After the acquisition, Hubexel and BioOrigin jointly developed new products U-Bone CEMENT (B-TCP bone cement) and U-Bone Putty (B-TCP + collagen). They also participated in a domestic academic conference exhibition last November.

Additionally, last month, Hubexel made its first delivery of raw materials extracted from PDRN and PN genes (DNA fragments) derived from the semen and testes of salmon and trout, which are used as cosmetic ingredients, to cosmetic and beauty-related clients.

PDRN stands for Polydeoxyribonucleotide and is known for promoting cell regeneration and growth as well as having excellent anti-inflammatory effects. It is mainly used in cases requiring cell regeneration within the body, such as musculoskeletal disorders and degenerative arthritis. Alongside this, PN (PolyNucleotide) is said to be effective for skin regeneration and tissue repair.

Going forward, Hubexel aims to complete the expansion and approval of B-GNP facilities at its subsidiary BioOrigin and directly produce additional medical device products. A company official stated, “We achieved our first product sales last month and are continuing additional sales this month. We expect significant product sales next year.” He emphasized, “We are thoroughly preparing to increase our sales revenue and net profit and to transfer to KOSDAQ by building a portfolio of marketable products including additional approved products, BioOrigin’s synthetic bone and biomaterial new products, and PN, PDRN cosmetic materials.”